Skip to content

A randomized, double-blind, single-center study of huperzine A injection on early postoperative cognitive function improvement in neurosurgical patients undergoing general anesthesia

A randomized, double-blind, single-center study of huperzine A injection on early postoperative cognitive function improvement in neurosurgical patients undergoing general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050023
Enrollment
Unknown
Registered
2021-08-16
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perioperative neurocognitive disorders

Interventions

Sponsors

Xinhua Hospital Affilated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 65 years old; 2. Meet the indications for neurosurgery under general anesthesia; 3. The patient agrees to participate in this trial, and he or his legal guardian signs the informed consent form before the trial.

Exclusion criteria

Exclusion criteria: 1. Liver and kidney insufficiency; 2. History of mental illness, long-term use of sedatives, antidepressants, etc.; 3. History of alcohol and drug abuse; 4. Severe systemic diseases, especially circulatory system diseases: such as myocardial infarction, heart failure, unstable angina, history of sinus bradycardia; 5. Those who cannot tolerate the experiment or cooperate with the inspection due to various reasons, various aphasia, audio-visual dysfunction, cognitive impairment, etc.; 6. Known allergic to Huperzine A; 7. Those who are positive for infectious disease screening; 8. Participated in other clinical trials within 3 months before the start of this study; 9. Systemic dysfunction, CFS-09 grading scale, in line with moderate frailty, severe frailty, very severe frailty and end-stage (such as social and mobility impairment) and/or frailty (2017 ESA guidelines recommend "CFS-09 nine-level classification" Law"); 10. Malnutrition: (1) Diagnostic method 1: BMI10% due to non-artificial factors, or the weight loss is >5% within 3 months; (3) On this basis, one of the following two points can be diagnosed: 1) BMI=70 years old); 2) FFMI<15Kg/m2 (female) or FFMI<17Kg/m2 (male); 11. Subjects deemed unsuitable by the investigator to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Mini-mental State Examination;

Secondary

MeasureTime frame
Montreal Cognitive Assessment;

Countries

China

Contacts

Public ContactLi Shiting

Xinhua Hospital Affilated to Shanghai Jiaotong University School of Medicine

lishiting@xinhuamed.com.cn+86 13701625911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026